selected publications
- Reply by Authors. The Journal of urology. 2020 Comment GET IT
-
Analysis of AR-FL and AR-V1 in Whole Blood of Patients with Castration Resistant Prostate Cancer as a Tool for Predicting Response to Abiraterone Acetate.
The Journal of urology.
2020
Academic Article
GET IT
Times cited: 7 -
Pharmacokinetics and Biodistribution of a [89Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer Patients.
Molecular pharmaceutics.
2019
Academic Article
GET IT
Times cited: 21 -
Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using 89Zr-DFO-MSTP2109A Anti-STEAP1 Antibody.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
2019
Academic Article
GET IT
Times cited: 32 -
Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2019
Academic Article
GET IT
Times cited: 218 -
A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2018
Academic Article
GET IT
Times cited: 130 -
Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet.
Annals of oncology : official journal of the European Society for Medical Oncology.
2018
Academic Article
GET IT
Times cited: 6 -
Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making.
JCO precision oncology.
2017
Academic Article
GET IT
Times cited: 302 -
OncoKB: A Precision Oncology Knowledge Base.
JCO precision oncology.
2017
Academic Article
GET IT
Times cited: 394 -
Alkaline phosphatase velocity predicts overall survival and bone metastasis in patients with castration-resistant prostate cancer.
Urologic oncology.
2017
Academic Article
GET IT
Times cited: 19 -
Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer.
European urology.
2016
Academic Article
GET IT
Times cited: 135 -
A Pilot Study of a Multimodal Treatment Paradigm to Accelerate Drug Evaluations in Early-stage Metastatic Prostate Cancer.
Urology.
2016
Academic Article
GET IT
Times cited: 39 -
Association of AR-V7 on Circulating Tumor Cells as a Treatment-Specific Biomarker With Outcomes and Survival in Castration-Resistant Prostate Cancer.
JAMA oncology.
2016
Academic Article
GET IT
Times cited: 486 -
Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate Cancer.
European urology.
2016
Academic Article
GET IT
Times cited: 111 -
Clinical Validity of Detecting Circulating Tumor Cells by AdnaTest Assay Compared With Direct Detection of Tumor mRNA in Stabilized Whole Blood, as a Biomarker Predicting Overall Survival for Metastatic Castration-Resistant Prostate Cancer Patients.
Cancer journal (Sudbury, Mass.).
2016
Academic Article
GET IT
Times cited: 48 -
Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2015
Academic Article
GET IT
Times cited: 310 -
Severe Hypocalcemia Associated With Denosumab in Metastatic Castration-Resistant Prostate Cancer: Risk Factors and Precautions for Treating Physicians.
2014
GET IT
Times cited: 24 -
Organoid cultures derived from patients with advanced prostate cancer.
Cell.
2014
Academic Article
GET IT
Times cited: 983 -
First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer.
British journal of cancer.
2013
Academic Article
GET IT
Times cited: 73 -
Mutational Analysis of Circulating Tumor Cells Using a Novel Microfluidic Collection Device and qPCR Assay.
Translational oncology.
2013
Academic Article
GET IT
Times cited: 161 -
Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2013
Academic Article
GET IT
Times cited: 203 -
Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival.
European urology.
2013
Academic Article
GET IT
Times cited: 58 -
Monitoring the clinical outcomes in advanced prostate cancer: what imaging modalities and other markers are reliable?.
Seminars in oncology.
2013
Review
GET IT
Times cited: 32 -
Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer.
The oncologist.
2013
Academic Article
GET IT
Times cited: 138 -
Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study.
The Lancet. Oncology.
2012
Academic Article
GET IT
Times cited: 91 -
Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors.
Cancer research.
2012
Academic Article
GET IT
Times cited: 163 -
TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate.
European urology.
2011
Academic Article
GET IT
Times cited: 170 -
Circulating tumor cells as biomarkers in prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2011
Review
GET IT
Times cited: 202 -
Circulating tumors cells as biomarkers: progress toward biomarker qualification.
Cancer journal (Sudbury, Mass.).
2011
Review
GET IT
Times cited: 71 -
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.
Lancet (London, England).
2010
Academic Article
GET IT
Times cited: 924 -
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2010
Academic Article
GET IT
Times cited: 379 -
Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2010
Academic Article
GET IT
Times cited: 362 -
Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2009
Academic Article
GET IT
Times cited: 176 -
Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survival.
Clinical chemistry.
2009
Academic Article
GET IT
Times cited: 117 -
Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2007
Academic Article
GET IT
Times cited: 559 -
Angioimmunoblastic T-cell lymphoma with an evolving Epstein Barr virus-positive diffuse large B-cell lymphoma with unusual clinical and pathologic findings.
Leukemia & lymphoma.
2007
Letter
GET IT
Times cited: 9 -
Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2007
Academic Article
GET IT
Times cited: 304 -
A pituitary-derived MEG3 isoform functions as a growth suppressor in tumor cells.
The Journal of clinical endocrinology and metabolism.
2003
Academic Article
GET IT
Times cited: 368 -
Overexpression of wild-type activin receptor alk4-1 restores activin antiproliferative effects in human pituitary tumor cells.
The Journal of clinical endocrinology and metabolism.
2002
Academic Article
GET IT
Times cited: 21 -
Loss of expression of GADD45 gamma, a growth inhibitory gene, in human pituitary adenomas: implications for tumorigenesis.
The Journal of clinical endocrinology and metabolism.
2002
Academic Article
GET IT
Times cited: 143 -
Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors.
The Journal of clinical endocrinology and metabolism.
2001
Academic Article
GET IT
Times cited: 80 -
Truncated activin type I receptor Alk4 isoforms are dominant negative receptors inhibiting activin signaling.
Molecular endocrinology (Baltimore, Md.).
2000
Academic Article
GET IT
Times cited: 46 -
Primary medical therapy of micro- and macroprolactinomas in men.
The Journal of clinical endocrinology and metabolism.
2000
Academic Article
GET IT
Times cited: 134 -
A human pituitary tumor-derived folliculostellate cell line.
The Journal of clinical endocrinology and metabolism.
2000
Academic Article
GET IT
Times cited: 41 -
Activin effects on neoplastic proliferation of human pituitary tumors.
The Journal of clinical endocrinology and metabolism.
2000
Academic Article
GET IT
Times cited: 48 -
Expression of prolactin-releasing peptide and its receptor messenger ribonucleic acid in normal human pituitary and pituitary adenomas.
The Journal of clinical endocrinology and metabolism.
1999
Academic Article
GET IT
Times cited: 27 -
Selective induction of apoptosis by the cytotoxic analog AN-207 in cells expressing recombinant receptor for luteinizing hormone-releasing hormone.
Proceedings of the National Academy of Sciences of the United States of America.
1999
Academic Article
GET IT
Times cited: 13